806 related articles for article (PubMed ID: 29461447)
1. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
2. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR; Zhao HZ; Chang LJ; Xu X; Gao Y; Li M; Kong QY; Wang MM; Zhao CF
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
7. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
8. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
Shao S; Zhou K; Liu X; Liu L; Wu M; Deng Y; Duan H; Li Y; Hua Y; Wang C
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4210-e4220. PubMed ID: 33837779
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
[TBL] [Abstract][Full Text] [Related]
11. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
[TBL] [Abstract][Full Text] [Related]
12. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[TBL] [Abstract][Full Text] [Related]
14. Facial nerve palsy may indicate coronary artery lesions in Kawasaki disease.
Chen J; Liu P; Hu W; Xu Y; Deng J
Clin Rheumatol; 2021 Oct; 40(10):4191-4197. PubMed ID: 34059986
[TBL] [Abstract][Full Text] [Related]
15. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease.
Türkuçar S; Yıldız K; Acarı C; Dundar HA; Kır M; Ünsal E
Turk J Pediatr; 2020; 62(1):1-9. PubMed ID: 32253860
[TBL] [Abstract][Full Text] [Related]
17. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
18. Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort.
Fabi M; Andreozzi L; Corinaldesi E; Bodnar T; Lami F; Cicero C; Tchana B; Landini C; Sprocati M; Bigucci B; Balsamo C; Sogno Valin P; Di Fazzio G; Iughetti L; Valletta E; Marchetti F; Donti A; Lanari M
Eur J Pediatr; 2019 Mar; 178(3):315-322. PubMed ID: 30499051
[TBL] [Abstract][Full Text] [Related]
19. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A; Pal P; Basu S
Rheumatol Int; 2019 Oct; 39(10):1797-1801. PubMed ID: 31302740
[TBL] [Abstract][Full Text] [Related]
20. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
Baek JS; Yu JJ; Kim MJ; You J; Jun HO; Kim YH; Ko JK
Pediatr Rheumatol Online J; 2018 Dec; 16(1):83. PubMed ID: 30594188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]